← FUURAA AI Frontier Library
ForecastIndustry, Economy & Capital1–3 years
Post-market monitoring is part of medical-AI design
Real-world populations, workflows and data can differ from premarket testing. Monitoring plans should anticipate drift, misuse and changes in clinical context.
U.S. Food and Drug Administration6 January 2025Reviewed 26 July 2026
FUURAA original conceptual visualWhat the evidence indicates
A concise reading of the source
Real-world populations, workflows and data can differ from premarket testing. Monitoring plans should anticipate drift, misuse and changes in clinical context.
FUURAA interpretation
Why this could matter
Define thresholds, investigation duties and corrective actions before deployment.
How to read this signal
A forward-looking synthesis, not a prediction of certainty
FUURAA has combined evidence with long-range reasoning. Readers should treat it as a question to examine, not as a statement of future fact.
